NEWS

Nanobactérie, whose AlphaOnco subsidiary is based at the BioArk in Monthey, announces a strategic partnership with EP Equity Investment (EPEI), a Luxembourg-based investment company.

ten23 health (based in Basel and at BioArk Visp) and Ypsomed announced that they are entering into a strategic partnership to advance thecommercialization of the YpsoDose wearable injector for subcutaneous self-injection of large-volume doses.

A delegation of around fifty international life sciences specialists visited BioArk in Monthey on 24 April. It was an opportunity to get to know the Valais ecosystem in this field, with presentations by Valais start-ups and a conference by the Idiap research institute on artificial intelligence. The visit to the Valais was organised as part of Swiss Biotech Day, one of the biggest life sciences events in Switzerland.

The HES-SO Valais-Wallis School of Engineering is today unveiling a major change in the way it promotes its educational offerings and research and innovation skills in the life sciences sector.
Over the past few years, the Swiss biopharmaceutical and food industries have undergone a rapid shift towards life sciences. Driven by innovation, collaboration and a commitment to health, wellbeing and sustainability, a number of partner companies of the Swiss College of Engineering (HEI), such as Debiopharm and Lonza, have massively expanded these business areas to meet the needs of the economy.